(Q37391122)

20 August 2017

1 reference

title

HIV-related liver disease: ARV drugs, coinfection, and other risk factors (English)

1 reference

20 August 2017

0 references

1 reference

1

Massimo Puoti

1 reference

20 August 2017

7

Giampiero Carosi

1 reference

20 August 2017

Paola Nasta

2

1 reference

20 August 2017

Francesca Gatti

3

1 reference

20 August 2017

Alessandro Matti

4

1 reference

20 August 2017

Katiela Prestini

5

1 reference

20 August 2017

Luciano Biasi

6

1 reference

20 August 2017

publication date

1 January 2009

1 reference

Journal of the International Association of Providers of AIDS Care

20 August 2017

published in

1 reference

20 August 2017

volume

8

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

30-42

1 reference

Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C.

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Grade 4 Events Are as Important as AIDS Events in the Era of HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Drug-induced liver disorders: implications for drug development and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Non-invasive evaluation of liver fibrosis using transient elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Abacavir hypersensitivity reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Abacavir hypersensitivity reaction: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Hepatic steatosis and HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Antiretroviral-associated liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Liver toxicity caused by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Initial antiretroviral therapy in chronically-infected HIV-positive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Natural history of chronic hepatitis B in co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Liver enzymes elevation after HAART in HIV-HCV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

An official ATS statement: hepatotoxicity of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Antituberculosis drug-induced hepatotoxicity: concise up-to-date review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109708330906

21 January 2018

Identifiers

DOI

10.1177/1545109708330906

1 reference

20 August 2017

1 reference